Stabilizing vimentin phosphorylation inhibits stem-like cell properties and metastasis of hybrid epithelial/mesenchymal carcinomas

Cell Rep. 2023 Dec 26;42(12):113470. doi: 10.1016/j.celrep.2023.113470. Epub 2023 Nov 20.

Abstract

Epithelial-mesenchymal transition (EMT) empowers epithelial cells with mesenchymal and stem-like attributes, facilitating metastasis, a leading cause of cancer-related mortality. Hybrid epithelial-mesenchymal (E/M) cells, retaining both epithelial and mesenchymal traits, exhibit heightened metastatic potential and stemness. The mesenchymal intermediate filament, vimentin, is upregulated during EMT, enhancing the resilience and invasiveness of carcinoma cells. The phosphorylation of vimentin is critical to its structure and function. Here, we identify that stabilizing vimentin phosphorylation at serine 56 induces multinucleation, specifically in hybrid E/M cells with stemness properties but not epithelial or mesenchymal cells. Cancer stem-like cells are especially susceptible to vimentin-induced multinucleation relative to differentiated cells, leading to a reduction in self-renewal and stemness. As a result, vimentin-induced multinucleation leads to sustained inhibition of stemness properties, tumor initiation, and metastasis. These observations indicate that a single, targetable phosphorylation event in vimentin is critical for stemness and metastasis in carcinomas with hybrid E/M properties.

Keywords: CP: Cancer; cancer stem cells, epithelial-mesenchymal transition, CSC, EMT, multinucleation, vimentin, metastasis, stemness, hybrid E/M, breast cancer.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma* / pathology
  • Cell Line, Tumor
  • Epithelial Cells / metabolism
  • Epithelial-Mesenchymal Transition
  • Humans
  • Intermediate Filaments* / metabolism
  • Intermediate Filaments* / pathology
  • Neoplasm Metastasis / pathology
  • Neoplastic Stem Cells / metabolism
  • Phosphorylation
  • Vimentin / metabolism

Substances

  • Vimentin